Silence Therapeutics (SLN) Expected to Announce Earnings on Wednesday

Silence Therapeutics (NASDAQ:SLN) is expected to be releasing its earnings data before the market opens on Wednesday, March 12th. Analysts expect Silence Therapeutics to post earnings of ($0.16) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Silence Therapeutics Price Performance

Shares of NASDAQ:SLN opened at $4.50 on Tuesday. The company has a market cap of $134.69 million, a P/E ratio of -2.87 and a beta of 1.08. Silence Therapeutics has a 1 year low of $4.06 and a 1 year high of $27.72. The stock’s fifty day moving average price is $5.35 and its 200-day moving average price is $11.26.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. BMO Capital Markets lowered their price target on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, March 4th. Chardan Capital reaffirmed a “buy” rating and set a $55.00 price target on shares of Silence Therapeutics in a report on Tuesday, December 10th. William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price target on shares of Silence Therapeutics in a report on Friday. Finally, Morgan Stanley lowered their price target on Silence Therapeutics from $49.00 to $45.00 and set an “overweight” rating on the stock in a report on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Silence Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $40.67.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.